Oragenics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Oragenics, Inc. on February 10, 2012, reporting a corporate governance event regarding executive compensation. The filing details an award of stock options to the Company's Chief Financial Officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to the specific stock option grant:
- Option Grant Size: 45,000 shares of common stock.
- Exercise Price: $1.20 per share (closing price on the grant date).
- Recipient: Michael Sullivan, Chief Financial Officer.
Material Changes
The material change reported is the execution of a new compensatory arrangement for the CFO under the Amended and Restated 2002 Stock Option and Incentive Plan. No changes to financial performance or capital structure are reported in this document.
Outlook, Risks, and Unusual Items
Management Commentary: The Board of Directors and Compensation Committee stated the award is intended to retain and motivate employees.
Vesting Schedule:
- 15,000 shares vested immediately.
- 15,000 shares vest on the first anniversary of the grant date.
- 15,000 shares vest on the second anniversary of the grant date.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2002 Stock Option and Incentive Plan to assess remaining capacity.
- Confirm the current market price of Oragenics common stock relative to the $1.20 exercise price.
- Review the Company's most recent 10-K or 10-Q for broader financial health and cash position, as this 8-K contains no operational financial data.